The spread of the Severe Acute Respiratory Syndrome-related novel coronavirus SARS-CoV-2 led to the global pandemic of the respiratory disease (COVID-19) in 2020. Researchers across the globe are working to develop potential treatments, vaccines and drugs to combat the new coronavirus and 2019-nCoV acute respiratory disease.
RT-PCR is the earliest method that can be applied in the detection of pathogens, and a real-time fluorescent RT-PCR positive result is widely utilized as a means of confirming coronavirus infection.
Diagnosis via nucleic acid detection is prone to a number of problems such as false negatives, long detection times and strict requirements in terms of equipment and lab personnel expertise. Additional CT scans and other clinical symptom indicators are often required for an accurate diagnosis of COVID-19.
A second emerging diagnostic method involves a patient’s serological indicators being tested positive for the specific IgM or IgG antibodies against 2019-nCoV.
Detection of antibodies is based on human immune responses to foreign pathogens, meaning that if pathogen-specific IgM is found in the serum, infection has occurred recently.
Specific IgG antibodies against pathogens can generally be detected after a 20 day period.
This can be used as an additional diagnostic approach when the nucleic acid test is found to be negative. 2019-nCoV testing guidelines outlined by the FDA state that antibody testing must not be used for the diagnosis of COVID-19 without additional methods to exclude or indicate the status of infection.
Catalogue no: C19S1-876
The 2019-nCoV High Sensitivity S1 Protein ELISA kit SignalChem offers a means of detecting the pathogen during the early stage of infection. The Spike glycoprotein (S) of coronavirus is a type I transmembrane protein containing two subunits: S1 and S2.
This protein is recognized as the key component in binding with host cells via the interaction with angiotensin-converting enzyme 2 (ACE2).
A receptor-binding domain (RBD) of S1 is able to recognize the cell surface receptor, meaning that mutation of RBD has the potential to cause increased motility rate.
The coronavirus employs a range of different proteins to replicate and invade cells, but this Spike protein is considered the primary surface protein used to bind to a receptor - a protein that acts as a doorway into a human cell.
SignalChem’s ELISA kit has been designed to detect and measure nCoV Spike protein in a range of complex biological samples, including pharyngeal swabs, saliva, or serum.
Figure 1. Assay workflow explaining mechanics of the 2019-nCoV High Sensitivity S1 Protein ELISA Kit. Image Credit: SignalChem Biotech Inc.
SignalChem: A global leader in cell signaling
SignalChem is a world leader in both cell signaling and protein engineering. Scientists at SignalChem have been undertaking research into the new coronavirus since its initial outbreak.
The company’s scientists have invested resources, time, and effort into comprehensively understanding the protein interaction map of the SARS-CoV-2.
This work is being done in order to engineer active recombinant SARS-CoV-2 and human proteins with a view to providing researchers worldwide with the tools and samples required for drug discovery research projects.
Advanced engineering technology and AI drug development software have allowed SignalChem to initiate a number of projects aimed at developing expression systems of key COVID-19 related proteins. These have included hot drug targets, for example, proteases and non-structural proteins (NSPs).
Each of these catalytically active proteins has been described as fully functional and ready for use in research into the development of drugs and treatments against SARS-CoV-2 and other novel coronavirus infections.
About SignalChem Biotech Inc.
SignalChem is a biotech company focused on the research, development, and production of innovative and high-quality human recombinant cell signaling products.
Throughout the years, Signalchem has capitalized on its core expertise in cellular signaling, molecular biology, and protein biochemistry to generate more than 2,000 functional protein products and has established itself as the leader in the industry to produce highly active human recombinant signaling enzymes, especially protein kinases, disease-related mutant kinases, lipid kinases, epigenetic enzymes, ubiquitination-related enzymes, and neurodegenerative disease-related enzymes and proteins.
SignalChem strives to support scientists in academia, pharma and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.